Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Utrecht – page 134

1 973 clinical trials in Utrecht, The Netherlands across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Utrecht at a glance
1 973
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

1 973 trials in Utrecht

Open in trial search

Diabetic nephropathy

Not recruiting

Study on the Effectiveness and Safety of Finerenone and Empagliflozin in Adults with Chronic Kidney Disease and Type 2 Diabetes

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Bayer AG

HIV infection

Not recruiting

Study on Reversing HIV Latency Using Pyrimethamine, Lenalidomide, and Panobinostat for People Living with HIV

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Cervix carcinoma stage II+1

Not recruiting

Study on Sentinel Node Detection in Early-Stage Cervical Cancer Using Indocyanine Green Compared to 99mTc and Blue Dye

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Indocyanine Green
  • Sponsor:Universitair Medisch Centrum Utrecht

Sarcoidosis

Not recruiting

Study on Azithromycin and Doxycycline for Reducing Inflammation in Sarcoidosis Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Azithromycin
  • Sponsor:Sint Antonius Ziekenhuis Stichting

Hereditary angioedema

Not recruiting

Study on NTLA-2002 for Adults with Hereditary Angioedema Using Ziclumeran and Lonvoguran

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Intellia Therapeutics Inc.

Myasthenia gravis

Not recruiting

Study on the Safety and Effectiveness of Gefurulimab for Adults with Generalized Myasthenia Gravis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Gefurulimab
  • Sponsor:Alexion Pharmaceuticals Inc.

Bladder transitional cell carcinoma

Not recruiting

Study on TAR-200 and Cetrelimab for High-Risk Bladder Cancer Patients Not Responding to BCG and Unable or Unwilling to Have Surgery

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Fibrodysplasia ossificans progressiva

Not recruiting

Study on the Safety and Effectiveness of Garetosmab for Adults with Fibrodysplasia Ossificans Progressiva

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Garetosmab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Chronic lymphocytic leukaemia

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab, Venetoclax, and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Genmab A/S

Hidradenitis

Not recruiting

Study on the Long-Term Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Heart failure with reduced ejection fraction

Not recruiting

Study on the Safety and Effectiveness of Tovinontrine for Adults with Chronic Heart Failure with Reduced Ejection Fraction

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Tovinontrine
  • Sponsor:Cardurion Pharmaceuticals Inc.

Non-small cell lung cancer

Not recruiting

Study Comparing Selpercatinib with a Drug Combination for Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Utrecht

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on TTR amyloidosis and heart disease treatments, investigating new therapeutic approaches for cardiac conditions. Clinical trials evaluate novel medications for improving patient mobility and cardiac function.

  • Heart Disease Management
  • Cardiac Biomarkers
  • Treatment Efficacy

Research aims to enhance quality of life for patients with hereditary and wild-type ATTR cardiomyopathy.

02 Cancer Research

Comprehensive studies in gastric cancer, bladder cancer, and neuroblastoma, exploring innovative treatment combinations and diagnostic methods.

  • Immunotherapy Applications
  • Targeted Therapies
  • Diagnostic Imaging

Advanced trials combining established treatments with novel approaches to improve patient outcomes.

03 Neurological Disorders

Groundbreaking research in Amyotrophic Lateral Sclerosis and chronic inflammatory conditions, focusing on innovative treatments and disease modification strategies.

  • Gene-Targeted Therapies
  • Neurological Function
  • Disease Progression

Studies aim to develop effective treatments for rare and challenging neurological conditions.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.